Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Common Equity: 2009-2025

Historic Common Equity for Lifecore Biomedical (LFCR) over the last 17 years, with May 2025 value amounting to $1.3 million.

  • Lifecore Biomedical's Common Equity fell 88.19% to $1.3 million in Q2 2025 from the same period last year, while for May 2025 it was $1.3 million, marking a year-over-year decrease of 88.19%. This contributed to the annual value of $1.3 million for FY2025, which is 88.19% down from last year.
  • As of FY2025, Lifecore Biomedical's Common Equity stood at $1.3 million, which was down 88.19% from $11.3 million recorded in FY2024.
  • In the past 5 years, Lifecore Biomedical's Common Equity ranged from a high of $201.9 million in FY2021 and a low of -$4.2 million during FY2023.
  • Its 3-year average for Common Equity is $2.8 million, with a median of $1.3 million in 2025.
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 104.82% in 2023, then spiked by 367.49% in 2024.
  • Lifecore Biomedical's Common Equity (Yearly) stood at $201.9 million in 2021, then plummeted by 56.51% to $87.8 million in 2022, then plummeted by 104.82% to -$4.2 million in 2023, then spiked by 367.49% to $11.3 million in 2024, then crashed by 88.19% to $1.3 million in 2025.